Research Analyst at UBS
No comprehensive public record could be found for Eliana Merrill as an analyst at UBS. There is no evidence of an Eliana Merrill serving in an analyst or research capacity covering specific companies at UBS, nor any verifiable career timeline, client coverage, credentials, or performance metrics on platforms such as LinkedIn, TipRanks, or relevant analyst rankings. It is possible that the individual does not hold such a position at UBS or is not a public-facing research analyst. No information regarding FINRA registrations or notable professional achievements for this name at UBS exists in available sources.
Eliana Merrill's representative asked for the company's latest estimates on the size of the addressable patient population for homozygous familial hypercholesterolemia (HoFH).
SVP Andy Davis stated that the literature suggests a prevalence for HoFH between one in 500,000 to one in a million people, and Arrowhead views the accessible patient population as being consistent with those estimates.